NovaBay Pharmaceuticals Q4 EPS $(0.21) Beats $(0.30) Estimate, Sales $3.73M Beat $3.40M Estimate
Portfolio Pulse from dijoy@benzinga.com
NovaBay Pharmaceuticals (AMEX:NBY) reported Q4 earnings with losses of $(0.21) per share, surpassing the $(0.30) estimate, and sales of $3.73M, exceeding the $3.40M estimate. This represents a significant improvement over the previous year's losses and a slight increase in sales.
March 26, 2024 | 9:18 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
NovaBay Pharmaceuticals reported better-than-expected Q4 earnings, with a significant reduction in losses and a slight increase in sales compared to last year.
The significant beat on both earnings and sales estimates, coupled with a substantial year-over-year improvement in financial performance, is likely to be viewed positively by investors. This could lead to increased investor confidence and a potential uptick in NBY's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100